Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Other Non-Current Liabilities: 2020-2022

Historic Other Non-Current Liabilities for Caribou Biosciences (CRBU) over the last 1 years, with Mar 2022 value amounting to $9,000.

  • Caribou Biosciences' Other Non-Current Liabilities was N/A to $9,000 in Q1 2022 from the same period last year, while for Mar 2022 it was $9,000, marking a year-over-year change of. This contributed to the annual value of $17,000 for FY2021, which is 90.34% down from last year.
  • Caribou Biosciences' Other Non-Current Liabilities amounted to $9,000 in Q1 2022, which was down 47.06% from $17,000 recorded in Q4 2021.
  • In the past 5 years, Caribou Biosciences' Other Non-Current Liabilities registered a high of $176,000 during Q4 2020, and its lowest value of $9,000 during Q1 2022.
  • Over the past 3 years, Caribou Biosciences' median Other Non-Current Liabilities value was $153,000 (recorded in 2021), while the average stood at $103,600.
  • Data for Caribou Biosciences' Other Non-Current Liabilities shows a maximum YoY tumbled of 90.34% (in 2021) over the last 5 years.
  • Quarterly analysis of 3 years shows Caribou Biosciences' Other Non-Current Liabilities stood at $176,000 in 2020, then tumbled by 90.34% to $17,000 in 2021, then reached $9,000 in 2022.
  • Its Other Non-Current Liabilities stands at $9,000 for Q1 2022, versus $17,000 for Q4 2021 and $153,000 for Q3 2021.